Gentamicin dosing and pharmacokinetics in low birth weight infants. 1988

S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
Neonatal Intensive Care Unit, Sendai Red Cross Hospital.

Monitoring of serum gentamicin concentrations and one-compartment pharmacokinetic analysis were performed in 41 preterm low birth weight infants (20 with birth weight of less than 1,500 g and 21 with birth weight of greater than or equal to 1,500 g) in the first week of life. Our dosing regimens, which were 2.0 mg/kg every 24 hr for the less than 1,500 g group and 2.0 mg/kg every 12 hr for the greater than or equal to 1,500 g group, successfully achieved the desired peak (4-8 micrograms/ml; 87.8%) and trough (less than or equal to 3 micrograms/ml; 97.5%) concentrations on the 4th day of treatment. In a one-compartment pharmacokinetic analysis, a large intersubject variability of pharmacokinetic parameters were observed on the 1st day of treatment. When we compared the parameters of the 1st day with those of the 4th day, apparent decreases in Vd and TBC were observed. The mean values for TBC and T1/2 or Kd of the two birth weight groups were significantly different from each other on the 4th day of treatment, suggesting a less maturity of renal functions in the less than 1,500 g group. The modified method of Sawchuk and Zaske was proven impractical in predicting steady-state serum concentrations because of an underestimation probably caused by the dramatic alteration of Vd due to a diuresis soon after birth. Based on these results, we recommend the above-described dosing regimen and emphasize the importance of a close monitoring of serum gentamicin concentrations and toxicities, instead of the individualized dosing approach in low birth weight infants in the first week of life.

UI MeSH Term Description Entries
D007230 Infant, Low Birth Weight An infant having a birth weight of 2500 gm. (5.5 lb.) or less but INFANT, VERY LOW BIRTH WEIGHT is available for infants having a birth weight of 1500 grams (3.3 lb.) or less. Low Birth Weight,Low-Birth-Weight Infant,Birth Weight, Low,Birth Weights, Low,Infant, Low-Birth-Weight,Infants, Low-Birth-Weight,Low Birth Weight Infant,Low Birth Weights,Low-Birth-Weight Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
January 1983, European journal of clinical pharmacology,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
March 2002, The Pediatric infectious disease journal,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
October 1986, The Journal of pediatrics,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
April 2022, Microbiology spectrum,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
January 1982, Developmental pharmacology and therapeutics,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
April 1988, The Journal of pediatrics,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
March 1986, British journal of clinical pharmacology,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
January 1985, Pediatric pharmacology (New York, N.Y.),
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
January 2023, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
S Nakae, and M Yamada, and T Ito, and Y Chiba, and E Sasaki, and M Sakamoto, and K Tada, and T Yamada, and S Mori
January 1977, Pediatrie,
Copied contents to your clipboard!